ES2192433B1 - Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno. - Google Patents

Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Info

Publication number
ES2192433B1
ES2192433B1 ES200002161A ES200002161A ES2192433B1 ES 2192433 B1 ES2192433 B1 ES 2192433B1 ES 200002161 A ES200002161 A ES 200002161A ES 200002161 A ES200002161 A ES 200002161A ES 2192433 B1 ES2192433 B1 ES 2192433B1
Authority
ES
Spain
Prior art keywords
rabbits
virus
antigen
disease
hemorragical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200002161A
Other languages
English (en)
Other versions
ES2192433A1 (es
Inventor
M. Del Rosario Fernandez Fernandez
Mercedes Mouriño
Jose Rivera Torres
Francisco Rodriguez
Juan Plana Duran
Juan Antonio Garcia Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Zoetis Manufacturing Research Spain SL
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Fort Dodge Veterinaria SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200002161A priority Critical patent/ES2192433B1/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Fort Dodge Veterinaria SA filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to EP01976170A priority patent/EP1317480A2/en
Priority to KR10-2003-7003067A priority patent/KR20030074593A/ko
Priority to NZ536683A priority patent/NZ536683A/en
Priority to CNB018181333A priority patent/CN100415891C/zh
Priority to PCT/EP2001/010026 priority patent/WO2002018426A2/en
Priority to CNA2008101283816A priority patent/CN101385854A/zh
Priority to AU9552501A priority patent/AU9552501A/xx
Priority to US10/363,503 priority patent/US20030186431A1/en
Publication of ES2192433A1 publication Critical patent/ES2192433A1/es
Application granted granted Critical
Publication of ES2192433B1 publication Critical patent/ES2192433B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/34011—Potyviridae
    • C12N2770/34041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/34043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Producción del antígeno VP60, o de un fragmento del mismo, del virus de la enfermedad hemorrágica de los conejos en plantas y vacuna contra la enfermedad hemorrágica vírica de los conejos que comprende dicho antígeno. El antígeno estructural VP60, o un fragmento del mismo, del virus de la enfermedad hemorrágica de los conejos (RHDV) se puede obtener en plantas utilizando un vector viral basado en el virus de la sharka (PPV) que comprende un promotor, una secuencia de DNA recombinante que comprende un cDNA al genoma del virus PPV, de longitud completa, y una secuencia de DNA que codifica a la proteína VP60 de RHDV, o un fragmento de la misma, insertada entre las secuencias de nucleótidos codificantes de las proteínas NIb y CP del virus PPV, y un vehículo de clonaje. El antígeno obtenido es capaz de inducir protección en conejos frente a una descarga letal de RHDV y puede utilizarse como vacuna subunitaria recombinante contra la enfermedad hemorrágica vírica de los conejos.
ES200002161A 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno. Expired - Fee Related ES2192433B1 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
ES200002161A ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.
KR10-2003-7003067A KR20030074593A (ko) 2000-09-01 2001-08-30 토끼 출혈병 백신 및 항원
NZ536683A NZ536683A (en) 2000-09-01 2001-08-30 Expression vectors of the VP60 antigen of RHDV based in teh plum pox virusf (PPV) and plants containing the vectors and vaccines
CNB018181333A CN100415891C (zh) 2000-09-01 2001-08-30 兔出血性疾病疫苗及抗原
EP01976170A EP1317480A2 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
PCT/EP2001/010026 WO2002018426A2 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
CNA2008101283816A CN101385854A (zh) 2000-09-01 2001-08-30 兔出血性疾病疫苗及抗原
AU9552501A AU9552501A (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens
US10/363,503 US20030186431A1 (en) 2000-09-01 2001-08-30 Rabbit hemorrhagic disease vaccine and antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200002161A ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Publications (2)

Publication Number Publication Date
ES2192433A1 ES2192433A1 (es) 2003-10-01
ES2192433B1 true ES2192433B1 (es) 2005-02-16

Family

ID=8494829

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200002161A Expired - Fee Related ES2192433B1 (es) 2000-09-01 2000-09-01 Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.

Country Status (8)

Country Link
US (1) US20030186431A1 (es)
EP (1) EP1317480A2 (es)
KR (1) KR20030074593A (es)
CN (2) CN101385854A (es)
AU (1) AU9552501A (es)
ES (1) ES2192433B1 (es)
NZ (1) NZ536683A (es)
WO (1) WO2002018426A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9474796B2 (en) 2012-08-14 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Crimean-Congo hemorrhagic fever virus vaccine
US9795665B2 (en) 2012-08-14 2017-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Attenuated live vaccine for Crimean-Congo hemorrhagic fever virus and Erve virus
CN103524615B (zh) * 2013-10-16 2015-04-15 四川理工学院 一种抗兔病毒性出血症病毒rhdv卵黄抗体的制备方法
CN107164252B (zh) * 2016-03-08 2020-10-20 上海海利生物技术股份有限公司 一种rhdv的亚单位疫苗
CN110302370A (zh) * 2019-07-04 2019-10-08 吉林建筑大学 一种苜蓿草植物疫苗的制备方法
CN115725511B (zh) * 2022-08-29 2024-02-09 四川农业大学 一种杂交瘤细胞株R2McAb2A1及其分泌的单克隆抗体和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
US5491076A (en) * 1993-11-01 1996-02-13 The Texas A&M University System Expression of foreign genes using a replicating polyprotein producing virus vector
ES2080024B1 (es) * 1994-07-06 1996-08-16 Univ Oviedo Vacuna subunitaria recombinante contra la enfermedad hemorragica virica de los conejos.
ES2139537B1 (es) * 1998-03-24 2000-10-01 Inmunologia & Genetica Aplic Sistema de presentacion de antigenos basado en el virus de la sharka.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CASTAÑON S. et al. "Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus", J. Virology, Vol. 73, nº 5, Mayo 1999, páginas 4452-4455. *

Also Published As

Publication number Publication date
WO2002018426A2 (en) 2002-03-07
ES2192433A1 (es) 2003-10-01
CN1630662A (zh) 2005-06-22
AU9552501A (en) 2002-03-13
US20030186431A1 (en) 2003-10-02
WO2002018426A3 (en) 2002-06-20
EP1317480A2 (en) 2003-06-11
NZ536683A (en) 2007-01-26
CN101385854A (zh) 2009-03-18
CN100415891C (zh) 2008-09-03
KR20030074593A (ko) 2003-09-19

Similar Documents

Publication Publication Date Title
CO2019009525A2 (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
CY1105680T1 (el) Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου
AR044724A1 (es) Promotores del virus de la rizadura amarilla del cestrum
JP2009544333A5 (es)
AR050102A1 (es) Polipeptidos de fusion de vih para la prevencion y /o tratamiento del sida
DK1349944T3 (da) Latensassocieret peptid af TGF-beta til at bibringe farmaceutisk aktive proteiner latens
ES2150416T3 (es) Vacuna virica defectiva producida por una linea celular complementada en trans.
CO5570710A2 (es) Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico
CO6210761A2 (es) Vectores de virus oncoliticos de viruela
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
AR061484A1 (es) Secuencias de adn vectores proteinas y usos de hemaglutinina de gripe aviar
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
MXPA05005202A (es) Vacuna.
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
ES2192433B1 (es) Produccion del antigeno vp60, o de un fragmento del mismo, del virus de la enfermedad hemorragica de los conejos en plantas y vacuna contra la enfermedad hemorragica virica de los conejos que comprende dicho antigeno.
JP2020509770A5 (es)
PE20161094A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
Vilček et al. Cellular insertions in the NS2-3 genome region of cytopathic bovine viral diarrhoea virus (BVDV) isolates
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
AR041765A1 (es) Vacuna a dna para la profilaxis y el tratamiento de infeccion por hiv
AR041764A1 (es) Vacuna basada en polinucleotidos y proteinas derivados del vih
DK1151079T3 (da) 1-deoxy-D-xylulose-5-phosphatreduktoisomerase og anvendelsesfremgangsmåder

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20031001

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192433B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180807